These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33525981)

  • 1. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
    Zhang Q; Xia T; Qi C; Du J; Ye C
    BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma.
    Jiang N; Li D; Han Y; Luo ZG; Liu LB
    Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of tumor associated neutrophils by PIK3CA expression in endometrial carcinoma from TCGA data.
    Pan Y; Jia LP; Liu Y; Han Y; Deng Q
    J Ovarian Res; 2019 Aug; 12(1):81. PubMed ID: 31472672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
    Li BL; Wan XP
    J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASPM, CDC20, DLGAP5, BUB1B, CDCA8, and NCAPG May Serve as Diagnostic and Prognostic Biomarkers in Endometrial Carcinoma.
    Zhang Q; Wang Y; Xue F
    Genet Res (Camb); 2022; 2022():3217248. PubMed ID: 36186000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
    Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
    Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
    Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
    Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a prognostic model of luteolin for endometrial carcinoma.
    Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
    Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
    Liu W; Sun L; Zhang J; Song W; Li M; Wang H
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
    Tian Y; Wen F; Wang S; Lv N
    Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
    Liu J; Ji C; Wang Y; Zhang C; Zhu H
    Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
    Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.